Chiral separation of lansoprazole and rabeprazole by capillary electrophoresis using dual cyclodextrin systems
Sign Up to like & getrecommendations! Published in 2019 at "ELECTROPHORESIS"
DOI: 10.1002/elps.201900107
Abstract: Novel capillary electrophoresis methods using CDs as chiral selectors were developed and validated for the chiral separation of lansoprazole and rabeprazole, two proton pump inhibitors. Fourteen different neutral and anionic CDs were screened at pH… read more here.
Keywords: capillary electrophoresis; separation lansoprazole; chiral separation; lansoprazole rabeprazole ... See more keywords
Rabeprazole Suppresses Cell Proliferation in Gastric Epithelial Cells by Targeting STAT3-mediated Glycolysis.
Sign Up to like & getrecommendations! Published in 2021 at "Biochemical pharmacology"
DOI: 10.1016/j.bcp.2021.114525
Abstract: The dysregulation of glycolysis leads to serials of disease. Rabeprazole is a representative of proton pump inhibitors and widely used in anti-ulcer treatment. However, the function of Rabeprazole on glycolysis in gastric epithelial cells remained… read more here.
Keywords: gastric epithelial; glycolysis; cell proliferation; rabeprazole ... See more keywords
Prompt drug delivery of rabeprazole through raft formation: In vitro and in vivo evaluation
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Drug Delivery Science and Technology"
DOI: 10.1016/j.jddst.2020.101932
Abstract: Abstract Rabeprazole is degraded in the stomach below 2.5 pH and the raft forming system keeps the stomach pH above 3.5. Above pH 3.5, rabeprazole is not degraded in the stomach. The present study aimed… read more here.
Keywords: delivery rabeprazole; raft; drug delivery; drug ... See more keywords
Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study
Sign Up to like & getrecommendations! Published in 2022 at "Chinese Medical Journal"
DOI: 10.1097/cm9.0000000000002508
Abstract: Abstract Background: The pharmacokinetic and clinical behaviors of many proton pump inhibitors (PPIs) in peptic ulcer treatment are altered by CYP2C19 genetic polymorphisms. This non-inferiority study evaluated the efficacy and safety of the novel PPI… read more here.
Keywords: safety; duodenal ulcers; rabeprazole; non inferiority ... See more keywords
Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole
Sign Up to like & getrecommendations! Published in 2023 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s391716
Abstract: Purpose Proton pump inhibitors (PPIs) are the first-line therapy for gastroesophageal reflux disorder (GERD). Unlike conventional PPIs, non-enteric coated PPIs with antacid salt enable a faster acid suppression through the rapid absorption of the PPI.… read more here.
Keywords: ypi 011; fixed dose; enteric coated; rabeprazole ... See more keywords
Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2021.690995
Abstract: Background: Proton pump inhibitors (PPIs) are validated gastric acid suppressors and have been widely used to treat patients with active duodenal ulcers. Although existing PPIs have shown great efficacy, many scientists are still devoted to… read more here.
Keywords: duodenal ulcers; clinical trial; anaprazole; safety ... See more keywords